文献速递核素与放射性配体治疗

肽受体放射性核素治疗对症状性转移性胰岛素瘤的临床控制有效:一项长期回顾性分析

Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis.
PubMed 文献 · J Nucl Med · 2024-02-01

这项长期回顾性研究纳入26例接受至少2周期[90Y]Y-DOTATOC或[177Lu]Lu-DOTATOC治疗的生长抑素受体阳性转移性恶性胰岛素瘤患者,评估肽受体放射性核素治疗(PRRT)对低血糖的改善、降糖药物变化及生存。治疗后81%患者低血糖评分下降,58%患者减少抗低血糖药物,中位总生存期19.7个月,中位无进展生存期11.7个月。

要点

  • PRRT后81%(21例)患者低血糖评分下降,其余5例稳定。
  • 58%(15例)患者抗低血糖药物用量减少。
  • 中位总生存期19.7个月,中位无进展生存期11.7个月。

核心结论

  • 据作者所知,本研究纳入了最大规模的恶性胰岛素瘤患者队列。
  • 大多数患者在接受后线PRRT后获得持久症状控制并减少抗低血糖药物。

研究设计与样本

  • 长期回顾性研究,纳入2000年初至2022年初接受至少2周期[90Y]Y-DOTATOC或[177Lu]Lu-DOTATOC治疗的组织学证实生长抑素受体阳性转移性恶性胰岛素瘤患者。
  • 32例患者中26例共接受106个[90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC周期被纳入分析。
  • 采用半定量评分系统量化背景抗低血糖治疗(生长抑素类似物、二氮嗪、依维莫司、皮质类固醇)下低血糖发作的严重程度和频率。

主要发现

  • 平均观察期21.5个月(范围2.3-107.4个月)。
  • 治疗前81%(n=21)患者低血糖评分为2分,19%(n=5)为1分。
  • PRRT后81%(n=21)患者评分下降,其余5例保持稳定。
  • 19%患者在注射[90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC后即刻出现低血糖暂时性加重。
  • 观察期内平均获益时间17.2个月(范围0-70.2个月)。

关键数值与推荐

  • 低血糖评分系统:0分无低血糖发作;1分需额外保守治疗并优化营养的低血糖事件;2分需住院和联合药物治疗的严重低血糖或低血糖昏迷史。
  • 获益时间定义为观察期内低血糖发作次数少于基线的时间范围。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastatic insulinoma is a rare malignant neuroendocrine tumor characterized by inappropriate insulin secretion, resulting in life-threatening hypoglycemia, which is often difficult to treat. There is currently very limited information about the efficacy of peptide receptor radionuclide therapy (PRRT) for clinical control of hypoglycemia. The aim of this long-term retrospective study was to evaluate the therapeutic efficacy of PRRT for improving hypoglycemia, to evaluate the change of medication after PRRT, and to calculate progression-free survival (PFS) and overall survival (OS). Methods: Inclusion criteria were histologically proven somatostatin receptor-positive metastatic malignant insulinoma and at least 2 cycles of [90Y]Y-DOTATOC or [177Lu]Lu-DOTATOC therapy from early 2000 to early 2022. A semiquantitative scoring system was used to quantify the severity and frequency of hypoglycemic episodes under background antihypoglycemic therapy (somatostatin analog, diazoxide, everolimus, corticosteroids): score 0, no hypoglycemic episodes; score 1, hypoglycemic events requiring additional conservative treatment with optimization of nutrition; score 2, severe hypoglycemia necessitating hospitalization and combined medication or history of hypoglycemic coma. Hypoglycemic score before and after PRRT was analyzed. Time of benefit was defined as a time range of fewer hypoglycemic episodes in the observation period than at baseline. Information on antihypoglycemic medication before and after therapy, PFS, and OS was recorded. Results: Twenty-six of 32 patients with a total of 106 [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC cycles were included. The average observation period was 21.5 mo (range, 2.3-107.4 mo). Before therapy, 81% (n = 21) of the patients had a hypoglycemia score of 2 and 19% (n = 5) had a score of 1. After PRRT, 81% of patients (n = 21) had a decreased score, and the remaining 5 patients showed a stable situation. There was temporary worsening of hypoglycemia just after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC in 19% of patients. The average time of benefit in the observation period was 17.2 mo (range, 0-70.2 mo). Antihypoglycemic medication reduction was achieved in 58% (n = 15) of patients. The median OS and PFS after the start of PRRT were 19.7 mo (95% CI, 6.5-32.9 mo) and 11.7 mo (95% CI, 4.9-18.5 mo), respectively. Conclusion: To our knowledge, our study included the largest cohort of patients with malignant insulinoma to be evaluated. Long-lasting symptom control and reduction of antihypoglycemic medications were shown in most patients after late-line PRRT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Friebe L, Freitag MT, Braun M, et al. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis. J Nucl Med. 2024. PMID: 38164592. doi:10.2967/jnumed.123.265894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。